Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2019
NICE publishes final recommendation for Almirall's Ilumetri (tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis
17 April 2019 - Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is ...
Posted by Michael Wonder on 20 Apr 2019
NICE final guidance published for Cimzia
18 April 2019 - NICE has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol). ...
Posted by Michael Wonder on 15 Apr 2019
No-deal risk recedes, but new Brexit delay adds to uncertainty
12 April 2019 - Delay means industry must sustain no-deal investment. ...
Posted by Michael Wonder on 14 Apr 2019
Cystic Fibrosis scandal: MP demands answers on delay of vital NHS drugs deal
11 April 2019 - Theresa May yesterday vowed to take action over the lack of an NHS deal for cystic fibrosis ...
Posted by Michael Wonder on 10 Apr 2019
Novartis’ Kisqali hit with NICE rejection
10 April 2019 - NICE has issued a draft guidance which does not recommend Novartis’ Kisqali (ribociclib), which is typically ...
Posted by Michael Wonder on 10 Apr 2019
#Orkambinow?
9 April 2019 - After a long standoff over CF treatment Orkambi, a deal looks imminent. ...
Posted by Michael Wonder on 08 Apr 2019
Prostate cancer hormone therapy rejected on NHS in England
8 April 2019 - A prostate cancer drug won't be offered on the NHS any earlier in the treatment plans of ...
Posted by Michael Wonder on 07 Apr 2019
Don’t attack NICE for relying on facts instead of emotion
3 April 2019 - The National Institute for Health and Care Excellence marks its 20th anniversary this week. ...
Posted by Michael Wonder on 07 Apr 2019
NICE appraisal for BMS kidney cancer immunotherapy combination
5 April 2019 - NICE has issued a Final Appraisal Determination endorsing NHS use of an Opdivo (nivolumab) and Yervoy ...
Posted by Michael Wonder on 02 Apr 2019
NICE nod for breast cancer delay drug
2 April 2019 - NICE has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for ...
Posted by Michael Wonder on 01 Apr 2019
No-deal Brexit could mean temporary medicines export ban
1 April 2019 - The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports ...
Posted by Michael Wonder on 01 Apr 2019
NICE: 20 years of evidence-based decision making
1 April 2019 - Founded in April 1999, the organisation has grown from one man with a borrowed laptop to a ...
Posted by Michael Wonder on 01 Apr 2019
Assessing data sources for medicine price studies
29 March 2019 - There is no established methodology to assess the feasibility of medicine price data sources. ...
Posted by Michael Wonder on 29 Mar 2019
Cystic fibrosis scandal: drugs deal moves a step closer to saving children
27 March 2019 - Officials are set to meet again “soon” with US drugs giant Vertex to “break the current impasse” ...
Posted by Michael Wonder on 28 Mar 2019
Promising lung cancer treatment approved for Cancer Drugs Fund
28 March 2019 - A promising new lung cancer treatment will be available on the NHS through the Cancer Drugs Fund, ...